Evaluation of the long-term efficacy and safety of lorlatinib

Lorlatinib is a third-generation ALK inhibitor, mainly used to treat ALK-positive non-small cell lung cancer, especially for patients who are resistant to first-generation drugs such as crizotinib or second-generation drugs such as alectinib. According to existing clinical research data, some patients can achieve long-term disease control after using lorlatinib, and even maintain efficacy after taking the drug for more than 3 years. Although individual differences are large, the potential for durable treatment of lorlatinib in ALK-positive patients has been clinically recognized.

From the perspective of long-term survival data, lorlatinib has shown good progression-free survival (PFS) and overall survival (OS) in phase II and III studies. After receiving treatment, the 3 yearPFS rate of some patients still remains at around 30%, especially in patients who have not received multiple lines of treatment or who are sensitive to drugs. The effect is more significant. More importantly, lorlatinib has a strong ability to control central nervous system (CNS) metastasis, and long-term use can continue to inhibit the progression of brain metastases.

In terms of safety, common adverse reactions of lorlatinib include high cholesterol, high triglycerides, peripheral edema, weight gain, and central nervous system-related symptoms such as cognitive changes and mood swings. Nonetheless, most side effects can be controlled under the guidance of a doctor by adjusting the dose, treating symptoms, or temporarily discontinuing the drug. For patients taking medication for a long time, regular monitoring of blood lipids, liver function, mental status and other indicators is the key to ensuring safe medication use.

In general, for some patients, it is possible to have sustained efficacy of lorlatinib for 3 years or even longer. The prerequisite for long-term treatment is that the disease does not progress and side effects are well controlled. Standardizing medication and conducting regular reviews under the guidance of a doctor is expected to achieve better treatment effects and quality of life.

Reference link:https://www.lorbrena.com/